



ISSN : 2347 - 2243

*Indo - American Journal of
Life Sciences and Biotechnology*



www.iajlb.com

Email : editor@iajlb.com or iajlb.editor@gmail.com



Design Plan for a Two-Group Randomized Trial of THR Products in Economically Developing Areas

M Kishore Babu¹, M Bhargavi², T Pavani³, D Divyasri⁴

1.Professor , Department of pharmaceutics , QIS College of pharmacy , Ongole , A.P

2.Assistant Professor , Department of Pharmacy practice , QIS College of pharmacy , Ongole , A.P

3.Assistant Professor , Department of Pharmacy practice , QIS College of pharmacy , Ongole , A.P

4.Assistant Professor , Department of Pharmacy practice , QIS College of pharmacy , Ongole , A.P

Abstract

As a result of increasing tobacco smoking, LMICs may account for a disproportionately high number of deaths caused by tobacco use worldwide. In order to deploy tobacco harm reduction (THR) products as an effective smoking cessation approach to limit escalating tobacco use in LMICs, it is vital to understand and perform RCTs in this setting. In this randomized controlled trial (RCT), 258 adult smokers will participate over the course of 52 weeks; each arm will get a 12-week treatment and a 12-week follow-up period. After participants fulfill the requirements and provide their informed permission, they will be randomly assigned to one of two treatment groups: (1) e-cigarettes with individual counseling and a nicotine patch dose of 21 mg or (2) nicotine patches with individual counseling and a nicotine concentration of 18 mg/ml. Both a screening and a baseline (BL) visit will be planned for participants at the trial location. A total of eight study visits, comprising five treatment sessions and three follow-up visits, will be arranged for the participants. These visits will include both in-person contacts at the trial site and telephone follow-up. In all, eight visits are scheduled for weeks 1, 2, 4, 8, 12, 18, 24, and 52. For the purpose of quantifying biochemically confirmed smoking abstinence, the trial site will use exhaled carbon monoxide evaluation.

Keywords: Smoking cessation, Tobacco harm reduction, E-cigarettes, Nicotine patches, LMIC

- Corresponding Author
Kishore babu
kishorebabu@gmail.com

INTRODUCTION

The increasing usage of tobacco causes a disproportionately high number of deaths in low- and middle-income countries (LMICs) throughout the world [1-3]. The weighted mean current smoking prevalence was 16.5% across 82 LMICs, with males being more likely to smoke than women. From 1.1% in Ghana to 50.6% in Kiribati, the prevalence of smoking tobacco differed across these nations [4]. In addition, 7.8 million people in lower-middle income nations and 2.1 million in low-income countries use e-cigarettes [5]. Tobacco smoking cessation programs should be prioritized by policymakers in order to lessen the impact of tobacco-related deaths and illnesses [6]. Additional research is needed to develop effective treatments for tobacco cessation due to the noticeable disparities in product usage and prevalence between high-income and low-income countries [1, 7]. The high rate of tobacco use in low and middle income countries has led to the adaptation of tobacco cessation programs from high-income nations to fit the local situation [8]. The efficacy of these studies is still debatable, nevertheless, because of cultural diversity and poor infrastructure in LMICs [9]. It is critical to perform clinical studies in LMICs to aid smoking cessation because of the growing tobacco usage and the problems it causes.

There have been a lot of research on smoking cessation, including observational and quasi-experimental studies, in Low- and middle-income countries (LMICs) have few randomized controlled trials (RCTs) on the topic of tobacco cessation [1]. India (n = 26, 28%), China (n = 17, 18%), and a total of 92 RCTs on tobacco cessation were identified in a thorough scoping analysis that included 138 LMICs. The next country is Thailand with 9 people (10%), then other countries with 40–44 per cent. Psychosocial interventions accounted for 57% of the total RCTs, psychosocial/behavioral interventions for 21%, and pharmacological/behavioral interventions for 9%.

to behavioral (n = 3, 3%), and pharmaceutical (n = 8, 9%). More than two-thirds of the programs specifically targeted non-brand smokers.



Pakistan was the site of six research, the most majority of which used psychosocial/pharmacological therapies (83%). Evidence quality was found to be weak in China compared to high-income nations, with the exception of psychosocial RCTs. RCTs were little compared to the huge cigarette death toll in the area [1], which affects all LMICs. Some of the primary obstacles to conducting tobacco cessation RCTs in LMICs include tobacco industry activities [10], patients' apparent unwillingness to quit smoking [11], a lack of knowledge about pharmacological therapies [12], and inefficient government policies [13]. In addition, there was a lack of emphasis on behavioral and pharmaceutical options in the randomised controlled trials (RCTs) pertaining to tobacco cessation in low- and middle-income countries (LMICs). According to the review's findings, even though there is some evidence from randomized controlled trials (RCTs) in low- and middle-income countries (LMICs), these countries are still not seen as having established best practices for tobacco cessation. As a result, effective tobacco control in LMICs requires local solutions that are tailored to their specific context [1]. While there have been some randomized controlled trials (RCTs) in low- and middle-income countries (LMICs) that have looked at the effectiveness of tobacco harm reduction (THR) products like e-cigarettes and nicotine replacement therapies (NRTs), the results have been inconclusive because the trials were either pilot studies or only included male smokers. This shows that more RCTs are needed to determine whether THR products are effective. The majority of the randomized controlled trials (RCTs) performed in low- and middle-income countries (LMICs) included nicotine patches, with only one research including electronic cigarettes and Korean male smokers. Clinical trials continue to be the gold standard for evaluating interventions, despite the problems associated with randomised controlled trials (RCTs), such as results being overgeneralized, limited sample sizes, validity, and reliability [17]. Research trials focusing on helping people quit smoking seem to be the gold standard for assessing the efficacy of tobacco control initiatives [18]. Using THR products as a smoking cessation approach to curb escalating tobacco use in LMICs requires understanding and performing RCTs in context to LMICs, considering the aforementioned shortcomings found by numerous research in LMICs. So yet, no randomized controlled trial (RCT) has been conducted to compare the efficacy of various THR products in adults in low- and middle-income countries.

MATERIALS AND METHODS

Study Design

The trial is a two-arm, parallel randomized controlled trial with a 12 weeks treatment duration and long-term 52 weeks follow-up. A schematic diagram of the trial design is given in **Figure 1**.




Figure 1. Schematic Diagram of Trial Design

Primary and Secondary Outcomes

This study's main endpoints will be:

- Commonality The number of individuals who self-reported not using any substances in the last seven days, with the



biochemical verification that their exhaled carbon monoxide levels were less than or equal to 10 parts per million.

When you come in for your stop date, therapy, and follow-up appointments, we'll check for the following secondary outcomes: Number of people who reported not smoking in the last week is called the "seven-day point prevalence."

- Cigarette Use: Participants recorded their daily cigarette smoking in their diaries.
- Participants' Opinions on the Product: Perceptions of EC or patch usage as measured by a modified cigarette assessment questionnaire. To measure how people feel about the product, we asked them twelve questions. The score may be anywhere from -6 to +6, with higher positive values indicating that a higher dosage has a stronger impact. To assess the likelihood of adverse events related to nicotine patches and EC, the Naranjo Adverse Drug Reaction Probability Scale will be used. Higher numbers indicate certain unfavorable medication effects, and the overall scores may range from -4 to +13.
- Dependence and Withdrawal Symptoms: To evaluate dependence and withdrawal symptoms, the Fagerstrom test for nicotine will be administered. It evaluates smoking frequency, dependency, and use quantity via six different components. A final score is generated by adding together all of the things.

from zero to ten. A higher score suggests that nicotine has a strong bodily impact on the user.

Dissemination and Ethics

All procedures related to the conduct of the research will adhere to the following: the Declaration of Helsinki, the Good Pharmacoepidemiology Practices Guidelines, the International Conference on Harmonization's Good Clinical Practice Guidelines, and any regulations that may be relevant to randomized controlled trials. All participants were asked to provide their informed permission before the trial began.

Subjects Under Investigation We will include adults in the research who use tobacco cigarettes and are motivated to stop from the general population in LMICs. **Eligibility Requirements for Participation** In order to be eligible to participate in the study, individuals must meet the following criteria: be of legal smoking age according to the country's laws; smoke only combustible cigarettes; have an exhaled carbon monoxide level greater than ten parts per million; desire to quit smoking; possess a mobile phone; be able to comply with all study procedures; and be available for follow-up. However, this medication will not be sold to pregnant or nursing women, anybody taking any other nicotine replacement therapy (NRT), anyone participating in a smoking cessation program or randomized controlled trial (RCT), and anyone with a history of cardiovascular disease or other serious illness for whom the prognosis is shorter than one year.

Recruiting and Scheduling

The trial site may be contacted by phone, email, or the study website; volunteers will be recruited via outpatient clinics and marketing. Permission from respondents is required for two phases in the consent process: screening and randomization. Participants are invited to the trial location for the zero visit, which consists of screening and signing a permission form, if they agree. Within two months of starting the experiment, the site will have recruited and identified all participants.

the very first hiring. As part of the screening process, the research coordinator will verify each response against the inclusion criteria checklist. Subsequently, we will collect baseline data and then randomly assign eligible participants to one of the two research arms, with research Arm A consisting of nicotine e-cigarettes and Study Arm B consisting of nicotine patches, at a ratio of 1:1. The lead investigator will utilize a web-based tool to produce a random sequence.

Medical Protocols

Study Arm A participants will get an EC device supply and nicotine cartridges (18 mg/ml) to last until their next in-person appointment. It is recommended that individuals familiarize themselves with ad libitum usage one week before to their stop date. On the quit day, participants will transition to using e-cigarettes for the subsequent twelve weeks. The majority of the studies used the 18 mg EC level, which is deemed an acceptable alternative for smokers who consume ten cigarettes or more per day [15].

In contrast, those assigned to the B group will get a supply of nicotine patches (21 mg) to last them until their next scheduled in-person appointment. The participants will put down the cigarette and start using the nicotine patch every day for 12 weeks on their designated quit day. Based on the results of the studies, the nicotine patch strength of 21 mg is a good alternative for



those who smoke 10 cigarettes or more each day [19-22].

Investigational Sites and Methods
The study location will arrange screening and baseline (BL) visits for participants. Through a mixed-mode approach that incorporates both in-person and telephone interactions with the respondents, a total of eight research visits—five treatment sessions and three follow-up visits—are planned for the participants.

Each of the eight research visits is planned for a different week: 1, 2, 4, 8, 12, 18, 24, and 52. A detailed description of the schedule of study visits is given in **Table 1**.

Table 1. Study Visit Schedule

Visit	Window	Visit Type	CRF	Questionnaires	Physical Measures	Counseling
Baseline	N/A	At Site	Yes	<ul style="list-style-type: none"> • Fagerstrom questionnaire • SCQoL • mCEQ • BDI-II 	<ul style="list-style-type: none"> • eCO breath test • BMI • Vital signs 	30 minutes
1 st Week	±2 days	Telephone	Yes	N/A	N/A	10 minutes
2 nd Week	±2 days	Telephone	Yes	N/A	N/A	10 minutes
4 th Week	±7 days	At Site	Yes	<ul style="list-style-type: none"> • Fagerstrom questionnaire • SCQoL • mCEQ • BDI-II 	<ul style="list-style-type: none"> • eCO breath test • BMI • Vital signs 	20 minutes
8 th Week	±2 days	Telephone	Yes	N/A	N/A	10 minutes
12 th Week	±7 days	At Site	Yes	<ul style="list-style-type: none"> • Fagerstrom questionnaire • SCQoL • mCEQ • BDI-II 	<ul style="list-style-type: none"> • eCO breath test • BMI • Vital signs 	15 minutes
18 th Week	±2 days	Telephone	Yes	N/A	N/A	10 minutes
24 th Week	±7 days	At Site	Yes	<ul style="list-style-type: none"> • Fagerstrom questionnaire • SCQoL • mCEQ • BDI-II 	<ul style="list-style-type: none"> • eCO breath test • BMI • Vital signs 	15 minutes
52 nd Week	±7 days	At Site	Yes	<ul style="list-style-type: none"> • Fagerstrom questionnaire • SCQoL • mCEQ • BDI-II 	<ul style="list-style-type: none"> • eCO breath test • BMI • Vital signs 	15 minutes



Loss to Follow Up

In comparison to other types of clinical trials, loss to follow-up in studies on quitting is often higher, with losses of 20–30% or more being common [23].

Safety Data Collection

Study staff will gather data on adverse events (AEs) at every follow-up appointment. It will be advised that participants who experience any adverse events (AEs) that might be linked to the investigational product contact the study team immediately if their symptoms worsen or change. Over the course of the follow-up period, the trial team will keep an eye out for adverse events. The PI will use the Naranjo Scale to assess and categorize all SAEs. The trial site's Data and Safety Monitoring Committee (DSMC) will keep an eye on any reports of serious adverse drug responses. In order to guarantee the safety of the trial participants, DSMC will establish an impartial stopping criteria based on the products' safety profiles.

We calculate the sample size. Twenty percent of smokers who used EC [24–27] reported a CO-validated decrease in smoking after six months, but just seven percent of smokers who used NRT [28] did the same. Research on smoking cessation also has a greater loss to follow-up rate than other clinical trial categories, with rates of 20-30% or more being reported often [23]. Our power analysis is predicated on previous studies that found an 11% disparity between the two groups, with 20% reporting smoking cessation in the e-cigarette group and 7% in the NRT group. With a two-sided significance level of 0.05, $\beta = 0.2$, and a 95% confidence interval, a sample size of 107 responses is needed for each group to obtain 80% power. According to the literature, a sample size of 258 was needed, with 129 responders in each arm, after accounting for a 20% dropout rate. Analysis of Data By regressing smoking status in each study arm, we will analyze the main and secondary outcomes of smoking cessation, reduction, and abstinence at each time point in the trial group. Using binomial regression, we will calculate the relative risk for both research groups. Primary analyses will be conducted to take the stratification factor into consideration.

modified to account for the location of the experiment, and baseline variables chosen by stepwise regression to conduct sensitivity analyses will also be modified. The mean differences between the two groups will be estimated at 95% confidence intervals using a generalized linear model with binary regressions. The variables that will be measured include product ratings, change scores for withdrawal symptoms at baseline and follow-up, and the number of participants who experienced adverse reactions. Furthermore, in order to analyze the main consequence, comprehensive case studies will be carried out. We will investigate time-to-relapse using Kaplan Meier curves, the log-rank test, and Cox proportional hazards regression analysis; for effect consistency for pre-specified subgroups based on demographic variables, we will employ test of heterogeneity. The Findings and Analysis Both clinical decision-making about the use of THR products for smoking cessation and the improvement of smoking abstinence among smokers in LMICs will be aided by the findings of this clinical investigation. We have identified a few issues with the research design. An important issue is the selection of intervention items. Despite the proliferation of electronic cigarette devices, very little is known about their safety or efficacy [29]. The effectiveness and acceptability of a particular e-cigarette model could affect the results obtained from studies. The trial will employ 21mg nicotine patches as they are the most regularly used product among NRTs. If you're worried that electronic cigarettes are causing any health problems, a patch may help you figure it out. People who use e-cigarettes say it takes a while to become used to them before they're pleased, and studies have shown that only new users experience high nicotine levels [30]. We gave participants detailed, illustrated instructions on how to use e-cigarettes and had them try them out for a week before they started trying to stop smoking in an effort to remedy this. Efficacy and safety will be reported throughout the trial's 12-week monitoring period. Twelve weeks should provide enough time to evaluate any unanticipated side effects. With these results, the Cochrane Systematic Review on e-cigarettes for reducing and quitting smoking will be much more comprehensive [31].

CONCLUSION

The purpose of this randomized controlled study is to determine if tobacco harm reduction products are safe and effective for adults in low- and middle-income countries. We expect this study's findings to add to and strengthen the body of evidence supporting e-cigarettes as a tool for smoking cessation.



REFERENCES

1. Kumar N, Janmohamed K, Jiang J, Ainooson J, Billings A, Chen GQ, + more. Smoking cessation in low- and middle-income nations: a systematic review and meta-analysis. *Research in Addiction*. 2021;112:106612.
2. The authors Sinha DN, Gupta PC, Kumar A, Bhartiya D, Agarwal N, Sharma S, and others wrote the following. A research including 140 nations found that the usage of smokeless tobacco had the biggest impact on the world's poorest people. *Journal of Nicotine Research*, 2018;20(12):1529–32.
3. Sreeramareddy CT, Harper S, Ernstsen L. Tobacco usage disparities by gender in 54 low- and middle-income nations: a study of education and wealth. *Public Health Reports*. 2018;27(1):26-34.
4. Theilmann M, Lemp JM, Winkler V, Manne-Goehler J, Marcus ME, Probst C, and others. Use of tobacco products and demographic information in 82 low- and middle-income nations: a nationally representative study. *American Journal of Medicine*. 2022;378.
5. Januszowicz T, Gavrilov GV, Shapiro H, and Król G. Projected number of people using electronic cigarettes throughout the world in 2020. The article is published in the *Harm Reduct Journal* and can be found on page 1-0 in 2021.
6. Ghebreyesus TA. The fight against the tobacco pandemic is making headway. The article is published in *The Lancet* on 2019-03-09. The DOI is 10989.
7. The group included Reitsma MB, Fullman N, Ng M, Salama JS, Abajobir A, Abate KH, and others. Global Burden of illness Study 2015: A systematic study of smoking prevalence and related illness burden in 195 countries and territories, 1990-2015. The article is published in *The Lancet* on 2017-09-18 and has the DOI: 389 and 10082.
8. Observations and recommendations from the field of tobacco intervention studies in low- and middle-income nations (Ward, K.D., 2008). The article is published in the *Journal of Smoke-Cessation* in 2016 and has the DOI: 11.0267.
9. Asfar T, Ward KD, Al-Ali R, Maziak W. Lessons learnt by the Syrian Center for Tobacco Studies: Building evidence-based tobacco therapy in the Eastern Mediterranean area. Article published in the *Journal of Smoking Cessation* in 2016 with the DOI: 11.2: 116-23.
10. Heydari G. and Batmanghelidj E. Cigarette smuggling, sanctions, and the Iranian government's licensing of major tobacco companies. *The International Journal of Preventive Medicine*, 2014, 5(2), 138.
11. Adhikari, Ashkani, Ahmadi, and Ahmadi, N. Nicotine gum, clonidine, and naltrexone maintenance therapy for tobacco use for twenty-four weeks. *Clinical Substance Abuse Treatment*. 2003;24(3):251-5.
12. The business sector's role in tobacco cessation programs (Zain Z.). *Substance abuse*. 2002 Aug;97(8):960-1.
13. Rosser A. Is contesting Indonesia's tobacco control policies. *Critique of Asian Studies*, 2015, 47(1), 69–93.
14. Authors: Lee SH, Ahn SH, and Cheong YS. Electronic cigarette use and its impact on smoking reduction and cessation among male smokers in Korea: A controlled trial. The next article is "J Am Board Fam Med" (2019, 32(4): 567–74).
Citation: 15. Zhao SZ, Wu YS, Chau SL, Fong DY, Lam TH, and Wang MP. A randomized controlled experiment investigating the efficacy of mobile chat-based assistance in conjunction with nicotine replacement treatment sampling to assist community smokers in quitting smoking. *The Tobacco Inducible Diseases journal* published the citation 2021.
15. Fables or foibles: inherent issues with RCTs (Rosner A., 2016). *Journal of Manipulative and Physiological Therapeutics*. 2003;26(7):460-7.
16. Morrison K. (2017). Some issues in determining "what works" in randomized controlled trials for evidence-based education. The article is published in *Eval Res Educ* and contains the following information: 69–83.
17. Hughes JR. Funding for tobacco control against evidence from science. *Public Health Perspectives*. 2007;32(5):449-50.
18. Pharmacotherapy for nicotine dependency 1. *California Cancer Journal Clinical* 2005;55(5):281-99. Authors:



- Henningfield JE, Fant RV, Buchhalter AR, and Stitzer ML. Twenty. George TP. Tobacco and nicotine. With Cecil medicine in Goldman's January 1, 2012, pages 142-146. WB George Saunders.
21. Lovinger RD. Essentials of addiction medicine for medical practitioners. Health Sciences Elsevier, 2019. No. 22: Vansickel AR, Cobb CO, Weaver MF, Eissenberg TE. The acute effects of electronic "cigarettes": a model for clinical laboratory evaluation of nicotine delivery profile, cardiovascular and subjective effects. *Journal of Cancer Epidemiology, Biomarkers, and Prevention*. 2010 Aug;19(8):1945–1953. 9. Eisenberg MJ, Hébert-Losier A, Filion KB, Windle SB. The E3 experiment is a randomized controlled study that aims to learn if electronic cigarettes help people quit smoking. 2(3):168–75. *CJC Open*. 2020. 24. The following authors contributed to the work: Rafful, García-Rodríguez, Wang, Secades-Villa, Martínez-Ortega, Blanco. A nationally representative sample of smokers was used to determine the factors that predicted both the number of tries to stop and the number of failed attempts. *Applied Behavior Analysis*. 2013;38(4):1920-3. 25. With contributions from Al-Delaimy WK, Myers MG, Leas EC, Strong DR, and Hofstetter CR. A population-based research on e-cigarette usage history and future stopping behavior. *Public Health Reports*, 2015, 105(6): 1213–9. 26. Hargraves, J.L., and Biener, L. A population-based research of adult smokers' usage of electronic cigarettes over time: correlation with smoking cessation and desire to stop. *Nicotine Tobacco Research*, 2015, 17(2), 127–33. 27. The authors of the study are Adriaens K, Belmans E, Van Gucht D, and Baeyens F. Researchers in Flanders found that electronic cigarette users had the same or even higher success rates in quitting smoking as those who used commonly prescribed smoking cessation aids. The study was published in the *Harm Reduct Journal* in 2021 and was conducted by Myers Smith et al. A randomized controlled experiment comparing the effectiveness of electronic cigarettes and nicotine replacement therapy as harm reduction strategies for smokers who struggle to stop. The authors of the article "Addiction" (Volume 117, Issue 1, pages 224–233) are Rodgers et al. Are you a smoker after texting? The outcomes of a randomized controlled study using text message interventions to help people quit smoking. *Control of Tobacco Use*. 2005;14(4):255-61.
30. The authors of the study are Caponnetto, Polosa, Auditore, Russo, and Campagna. Helping smokers who have a history of depression and relapses quit using electronic cigarettes. The fatal intravenous injection of refilling solution for an electronic nicotine delivery system was reported by Thornton SL, Oller L, and Sawyer T in the *International Journal of Clinical Medicine* in 2011. *Johns Hopkins University Journal of Medical Toxicology*. 2014;10:202-4.